• Dlin-MC3-DMA for Smarter LNP RNA Delivery

  2026-09-09

  Dlin-MC3-DMA is an ionizable cationic liposome lipid for building potent LNPs that support hepatic siRNA delivery and mRNA vaccine formulation. This practical guide connects its pH-responsive behavior with formulation workflow, machine-learning-guided optimization, comparative performance, and troubleshooting decisions.

• Direct Mouse Genotyping Kit Plus for Study Integrity

  2026-09-08

  The Direct Mouse Genotyping Kit Plus supports a genotype-first strategy for reliable mouse genotyping assay design. This article connects rapid direct PCR with mechanistic studies of SCA3/MJD mice, showing how pre-analytic genetic quality control strengthens interpretation without overstating what genotype data can prove.

• MK-0812 Workflows for CCR2 Inflammation Research

  2026-09-08

  MK-0812 enables precise interrogation of CCR2-dependent monocyte trafficking from whole-blood pharmacology to gut–liver inflammation models. This practical guide connects validated MCP-1 blockade with experimental designs for MASH mechanism studies while clearly separating established performance from exploratory applications.

• RBMS1 Loss Enables PD-L1 Blockade in TNBC

  2026-09-07

  The reference study identifies the RNA-binding protein RBMS1 as a post-transcriptional regulator of PD-L1 stability in triple-negative breast cancer. Its depletion destabilizes B4GALT1 mRNA, reduces PD-L1 glycosylation, promotes PD-L1 degradation, and improves T-cell-mediated tumor control when combined with checkpoint or CAR-T strategies.

• Docetaxel Workflows for Tumor Models

  2026-09-07

  Docetaxel provides a practical microtubule-stabilizing benchmark for cancer chemotherapy research, from monolayer cytotoxicity assays to patient-derived gastric cancer assembloids. This guide translates its mechanism into reproducible dosing, orthogonal response measurements, and tumor–stroma experiments designed to expose treatment resistance.

• Chlorpromazine HCl: Endocytosis & Neuropharmacology

  2026-09-05

  Chlorpromazine HCl is more than a conventional phenothiazine antipsychotic: it is a practical probe for dopamine receptor inhibition and clathrin-dependent cellular uptake. This guide shows how to integrate it into S2-cell infection assays, neuronal experiments, controls, and troubleshooting workflows without confusing endocytosis effects with general cytotoxicity.

• Erastin: Mechanism and Ferroptosis Research Guide

  2026-09-04

  Erastin is a small-molecule ferroptosis inducer used to model iron-dependent oxidative cell death in cancer biology research. It connects RAS/BRAF-associated tumor vulnerability with system Xc⁻ inhibition, glutathione depletion, and lipid-peroxide accumulation, while product handling requires fresh DMSO preparation and controlled storage.

• A-1210477: Translating MCL-1 Dependence

  2026-09-04

  A mechanistic and translational framework for using A-1210477 to distinguish MCL-1-dependent cancer cell survival from simple protein overexpression, validate mitochondrial apoptosis, and design more informative combination studies.

• GSK126: An EZH2 Inhibitor for Chromatin-Context Studies

  2026-09-03

  GSK126 is a selective EZH2 inhibitor for dissecting PRC2-dependent H3K27me3 and gene silencing. This article uses a decidual CXCL10 study to develop a context-aware framework for cancer epigenetics research, assay design, and translational interpretation.

• IEM 1460: AMPA Receptor Blocker Workflows

  2026-09-03

  IEM 1460 enables controlled AMPA receptor inhibition for experiments on excitotoxicity, synaptic signaling, and neuronal survival. This practical guide connects assay design, handling, controls, and troubleshooting with insights from recent glutamate-receptor research while clearly separating validated findings from optimization recommendations.

• Ferroptosis Inducers in Advanced Prostate Cancer

  2026-09-02

  Ghoochani and colleagues provide preclinical evidence that treatment-resistant prostate cancer retains ferroptosis-associated vulnerabilities and responds to the ferroptosis inducers Erastin and RSL3. Their study is notable for combining ferroptosis induction with second-generation anti-androgens, linking redox-targeted cell death to a clinically relevant strategy for advanced disease.

• TEAD2 and Ferroptosis in Hepatocellular Carcinoma

  2026-09-02

  The reference study integrates multi-database bioinformatics with in vitro validation to position TEAD2 as a prognostic candidate and regulator of ferroptotic vulnerability in hepatocellular carcinoma. Its findings connect TEAD2 expression with survival, immune-cell infiltration, iron accumulation, and oxidative damage, while also highlighting the need for orthogonal validation before clinical translation.

• Necrosulfonamide (NSA): MLKL Inhibitor Guide

  2026-09-01

  Necrosulfonamide (NSA) is a selective MLKL inhibitor for mechanistic necroptosis assays. It blocks phosphorylated MLKL translocation and membrane disruption without suppressing MLKL phosphorylation, with a reported HT-29 necroptosis IC50 of approximately 124 nM.

• Vernakalant for Rapid Conversion of Atrial Fibrillation

  2026-09-01

  The ACT-III trial evaluated intravenous vernakalant hydrochloride, also known as RSD1235, as a rapid pharmacological strategy for converting recent-onset atrial fibrillation to sinus rhythm. Its randomized, placebo-controlled design showed substantially greater conversion with vernakalant than placebo, while also identifying important limits for safety interpretation and patient selection.

• H3K18 Lactylation Drives CRC via METTL5–CCT2

  2026-08-31

  This 2026 study identifies a lactate-responsive H3K18 lactylation–METTL5–CCT2 axis that promotes colorectal cancer progression by suppressing pyroptosis. Its integrated tissue, epigenomic, transcriptomic, and functional analyses connect metabolic reprogramming with RNA methylation and inflammasome regulation, while supporting further evaluation of AZD6482 plus oxaliplatin in preclinical models.

8017 records 1/535 page Next 12345 下5页 Last page